“The simplSEQ workflow offers many workflow advantages over other methods of cell-free DNA extraction especially speed, simplicity, reproducibility, which are
“The simplSEQ workflow offers many workflow advantages over other methods of cell-free DNA extraction especially speed, simplicity, reproducibility, which are
Company Filed Second Patent Application to Extend Core Technology Applications
Murrieta Genomics is pleased to announce that U.S. Patent and Trademark
Murrieta Genomics, the launch pad for genomic sequencing startups, is pleased to announce that simplSEQ, an incubator company and subsidiary,
“Our first product is a kit for the purification and isolation of nucleic acids from plasma that we believe will
“The simplSEQ workflow offers many workflow advantages over other methods of cell-free DNA extraction especially speed, simplicity, reproducibility, which are
Company Filed Second Patent Application to Extend Core Technology Applications
Murrieta Genomics is pleased to announce that U.S. Patent and Trademark
Murrieta Genomics, the launch pad for genomic sequencing startups, is pleased to announce that simplSEQ, an incubator company and subsidiary,
“Our first product is a kit for the purification and isolation of nucleic acids from plasma that we believe will
“The simplSEQ workflow offers many workflow advantages over other methods of cell-free DNA extraction especially speed, simplicity, reproducibility, which are
Company Filed Second Patent Application to Extend Core Technology Applications
Murrieta Genomics is pleased to announce that U.S. Patent and Trademark
Murrieta Genomics, the launch pad for genomic sequencing startups, is pleased to announce that simplSEQ, an incubator company and subsidiary,
“Our first product is a kit for the purification and isolation of nucleic acids from plasma that we believe will
“The simplSEQ workflow offers many workflow advantages over other methods of cell-free DNA extraction especially speed, simplicity, reproducibility, which are
Company Filed Second Patent Application to Extend Core Technology Applications
Murrieta Genomics is pleased to announce that U.S. Patent and Trademark
Murrieta Genomics, the launch pad for genomic sequencing startups, is pleased to announce that simplSEQ, an incubator company and subsidiary,
“Our first product is a kit for the purification and isolation of nucleic acids from plasma that we believe will
Murrieta Genomics start-up TX Genetic Research was recently awarded second place in a national competition held by Golden Helix,
Murrieta Genomics, the
provider of genomics services and a launch pad for genomic sequencing startups,
will be hosting a lunch and learn
Murrieta Genomics, the provider of genomics services and a launch pad for genomic sequencing startups, has signed a tenancy agreement
Tx Genetic Research was founded on the goal of helping people treat their “inside skin” well for life.
On Friday, January 29th 2021 an article about Murrieta Genomics and our wholly owned subsidiary, SimplSEQ, was published by GenomeWeb.
The RuleOut team has created a novel approach that can exponentially increase COVID-19 testing capacity.
Life Science Nation provides an incredibly important service to early stage life science companies by connecting them with products, services
John Powers, President of Murrieta Genomics and CEO of SimplSeq, our wholly owned subsidiary, was interviewed recently on Beyone with